International Medical (000516): Robust growth in patient visits, Q1 losses significantly narrowed with recovery prospects.

On April 24, 2026, the company released its 2025 annual report and Q1 2026 financial report. In 2025, the company achieved operating revenue of 4.075 billion yuan, representing a year-on-year decrease of 15.39%; net profit attributable to shareholders was -313 million yuan.

Guosheng SecuritiesMay 15 19:41

International Medical (000516): Short-term performance pressure, hospital treatment volume remains advantageous

Event: The company released its financial performance report for 2025 and Q1 2026. In 2025, the company achieved revenue of 4.07 billion yuan (-15.4%) and reported a net loss attributable to shareholders of 310 million yuan, representing a 23.2% increase in losses year-on-year. Performance declined.

Southwest SecuritiesApr 29 00:00

International Medical: First Quarter Report for 2026

SZSIApr 24 00:00 · Announcements

International Medical: Summary of the 2025 Annual Report

SZSIApr 24 00:00 · Announcements

International Medical: 2025 Annual Report

SZSIApr 24 00:00 · Announcements

The release of national standards such as brain-computer interface marks the industry's official transition from 'planning blueprint' to 'fast track for implementation.' Institutions are optimistic about these two sectors.

① Brain-computer interfaces have officially transitioned from the technology exploration phase into clinical application, opening up commercialization opportunities in the fields of neural modulation and implantable medical devices; ② In just the first quarter of this year, the total financing amount for brain-computer interface companies has already surpassed the entire year of 2025, with industry momentum continuing to rise.

cls.cnApr 11 17:02